Učitavanje...
Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
Upadacitinib plasma concentrations, efficacy, and safety data from 216 subjects with moderate‐to‐severe active Crohn's disease (CD) from the 16‐week induction period of the CELEST study were analyzed to characterize upadacitinib exposure–response relationships in CD. Subjects in CELEST received...
Spremljeno u:
| Izdano u: | Clin Pharmacol Ther |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027977/ https://ncbi.nlm.nih.gov/pubmed/31594037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1668 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|